It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia, and acceptance for a grant in China.
“We look forward to continuing to advance Modi-1, the first product from this platform, towards clinical development," said chief executive, Dr Cliff Holloway.
Moditope is one of two platforms the company has developed – the other is ImmunoBody, which has spawned SCIB-1 and SCIB-2, which target and stimulate existing cells that make up the body’s defence mechanisms.
The UK group is planning to use SCIB1 in harness with Merck’s Keytruda checkpoint inhibitor to treat patients with advanced melanoma.
In mid-morning trading, shares in Scancell were up 2% at 5.2p.
-- Adds share price --